Computationally repurposing drugs for breast cancer subtypes using a network-based approach

BMC Bioinformatics

Table 11 Top 20 drugs corresponding to subtype 10

Rank	Drug	Dosage (μm)	Treatment time (h)	Score	Drug type	References
1	Ruxolitinib	10	24	− 0.71	Approved	[51, 52]
2	Bitopertin	10	24	− 0.66	Investigational
3	ICI-185,282	0.04	24	− 0.66	Experimental
4	Tranilast	0.04	24	− 0.65	Investigational	[68]
5	Bafilomycin A1	0.05	6	− 0.65	Experimental
6	EDTA	10	24	− 0.64	Approved	[93]
7	MK-1775	10	24	− 0.63	Investigational	[109, 110]
8	Emtricitabine	10	24	− 0.63	Approved	[114]
9	Etofylline-Clofibrate	10	24	− 0.63	Approved
10	PF-04217903	0.04	24	− 0.61	Investigational
11	Sapitinib	10	24	− 0.61	Investigational	[85]
12	Bisoprolol	10	24	− 0.61	Approved	[107]
13	Fingolimod	0.04	24	− 0.61	Approved	[82]
14	XMD11-85h	0.04	3	− 0.61	Experimental
15	PHA-767491	10	24	− 0.6	Experimental	[83]
16	Finasteride	10	24	− 0.6	Approved	[105]
17	Ribavirin	10	24	− 0.6	Approved	[65]
18	Labetalol	0.04	24	− 0.6	Approved
19	MG-132	20	24	− 0.6	Experimental	[111]
20	Deferiprone	0.04	24	− 0.59	Approved	[66, 67]

ISSN: 1471-2105